Sonoma Pharmaceuticals Stock Probability Of Bankruptcy

SNOA Stock  USD 2.68  0.05  1.90%   
Sonoma Pharmaceuticals' odds of distress is above 80% at this time. It has very high probability of going through financial hardship in the upcoming years. Chance of distress shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Sonoma balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Sonoma Pharmaceuticals Piotroski F Score and Sonoma Pharmaceuticals Altman Z Score analysis.
For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.
  
As of December 25, 2024, Market Cap is expected to decline to about 8.4 M. In addition to that, Enterprise Value is expected to decline to about 4.8 M

Sonoma Pharmaceuticals Company chance of distress Analysis

Sonoma Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

 = 

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Sonoma Pharmaceuticals Probability Of Bankruptcy

    
  Over 80%  
Most of Sonoma Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sonoma Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Sonoma Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Sonoma Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Sonoma Pharmaceuticals financial health.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.99)
Revenue Per Share
20.967
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.20)
Return On Equity
(0.75)
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sonoma Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Sonoma Pharmaceuticals is extremely important. It helps to project a fair market value of Sonoma Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Sonoma Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sonoma Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sonoma Pharmaceuticals' interrelated accounts and indicators.
0.86-0.730.880.22-0.19-0.570.210.25-0.53-0.68-0.23-0.30.670.340.170.29-0.490.17-0.09-0.040.06
0.86-0.860.76-0.3-0.33-0.260.210.11-0.79-0.39-0.59-0.070.630.59-0.090.12-0.53-0.120.170.12-0.04
-0.73-0.86-0.740.280.090.03-0.070.190.580.270.57-0.11-0.36-0.790.30.130.280.28-0.44-0.450.16
0.880.76-0.740.18-0.44-0.640.360.3-0.31-0.66-0.06-0.30.260.310.270.45-0.660.29-0.2-0.150.09
0.22-0.30.280.180.28-0.56-0.010.250.54-0.510.71-0.40.06-0.490.50.310.090.56-0.5-0.320.2
-0.19-0.330.09-0.440.280.48-0.45-0.430.220.21-0.050.170.180.15-0.44-0.690.88-0.310.50.53-0.27
-0.57-0.260.03-0.64-0.560.48-0.27-0.590.020.83-0.410.7-0.150.41-0.69-0.750.66-0.550.70.65-0.31
0.210.21-0.070.36-0.01-0.45-0.270.540.0-0.170.15-0.24-0.11-0.170.350.3-0.50.6-0.3-0.43-0.21
0.250.110.190.30.25-0.43-0.590.54-0.04-0.510.28-0.750.1-0.360.40.52-0.450.44-0.55-0.730.02
-0.53-0.790.58-0.310.540.220.020.0-0.040.180.80.04-0.65-0.410.280.050.380.41-0.32-0.230.17
-0.68-0.390.27-0.66-0.510.210.83-0.17-0.510.18-0.180.8-0.30.08-0.25-0.340.44-0.20.240.24-0.09
-0.23-0.590.57-0.060.71-0.05-0.410.150.280.8-0.18-0.31-0.43-0.570.670.40.010.59-0.63-0.530.3
-0.3-0.07-0.11-0.3-0.40.170.7-0.24-0.750.040.8-0.31-0.060.32-0.29-0.310.33-0.230.310.43-0.04
0.670.63-0.360.260.060.18-0.15-0.110.1-0.65-0.3-0.43-0.060.27-0.1-0.04-0.03-0.120.10.07-0.05
0.340.59-0.790.31-0.490.150.41-0.17-0.36-0.410.08-0.570.320.27-0.65-0.510.17-0.60.730.66-0.25
0.17-0.090.30.270.5-0.44-0.690.350.40.28-0.250.67-0.29-0.1-0.650.83-0.530.76-0.92-0.810.39
0.290.120.130.450.31-0.69-0.750.30.520.05-0.340.4-0.31-0.04-0.510.83-0.760.66-0.89-0.80.25
-0.49-0.530.28-0.660.090.880.66-0.5-0.450.380.440.010.33-0.030.17-0.53-0.76-0.440.520.49-0.17
0.17-0.120.280.290.56-0.31-0.550.60.440.41-0.20.59-0.23-0.12-0.60.760.66-0.44-0.77-0.680.2
-0.090.17-0.44-0.2-0.50.50.7-0.3-0.55-0.320.24-0.630.310.10.73-0.92-0.890.52-0.770.93-0.36
-0.040.12-0.45-0.15-0.320.530.65-0.43-0.73-0.230.24-0.530.430.070.66-0.81-0.80.49-0.680.93-0.23
0.06-0.040.160.090.2-0.27-0.31-0.210.020.17-0.090.3-0.04-0.05-0.250.390.25-0.170.2-0.36-0.23
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition

Based on the latest financial disclosure, Sonoma Pharmaceuticals has a Probability Of Bankruptcy of 80%. This is 84.8% higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 100.85% lower than that of the firm.

Sonoma Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sonoma Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sonoma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Sonoma Pharmaceuticals by comparing valuation metrics of similar companies.
Sonoma Pharmaceuticals is currently under evaluation in probability of bankruptcy category among its peers.

Sonoma Pharmaceuticals Main Bankruptcy Drivers

201920202021202220232024 (projected)
Return On Assets(0.2)(0.31)(0.27)(0.32)(0.33)(0.34)
Asset Turnover1.31.240.670.820.860.74
Net Debt(2.2M)(1.5M)(6.0M)(3.0M)(2.5M)(2.6M)
Total Current Liabilities4.9M4.1M5.8M3.7M3.7M3.7M
Non Current Liabilities Total991K5.5M4.3M4.5M4.9M5.1M
Total Assets14.6M15.0M18.8M16.2M14.7M15.3M
Total Current Assets12.4M13.0M16.4M13.8M12.5M12.6M
Total Cash From Operating Activities(4.6M)(3.4M)(4.2M)(6.2M)(2.4M)(2.5M)

Sonoma Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sonoma Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sonoma Pharmaceuticals' managers, analysts, and investors.
Environmental
Governance
Social

Sonoma Fundamentals

About Sonoma Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sonoma Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sonoma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sonoma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:
Check out Sonoma Pharmaceuticals Piotroski F Score and Sonoma Pharmaceuticals Altman Z Score analysis.
For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.99)
Revenue Per Share
20.967
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.20)
Return On Equity
(0.75)
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.